Day: August 21, 2020

Takeda Suspends Screening & Further Enrollment in TAK-754, TAK-748 Clinical Studies

The following is an excerpt from an update from Takeda. Read the update in its entirety here. Takeda recently informed HFA of it’s decision to suspend screening and further enrollment in the TAK-754 and TAK-748 clinical studies, effective immediately.TAK-754 is an AAV8 gene therapy for the treatment of hemophilia A currently in Phase 1/2 clinical development, while TAK-748 […]